WO2012086341A1

WO2012086341A1 - Liquid oral composition

Info

Publication number: WO2012086341A1
Application number: PCT/JP2011/076349
Authority: WO
Inventors: 沙織滝; 洋子明間; 安雄野村
Original assignee: ライオン株式会社
Priority date: 2010-12-24
Filing date: 2011-11-16
Publication date: 2012-06-28
Also published as: JP5691494B2; KR101807905B1; JP2012131755A; KR20130132858A; CN103269676A; MY162993A; CN103269676B

Abstract

Provided are: a liquid oral composition in which an ascorbic acid phosphate ester compound is mixed, wherein the stability of the ascorbic acid phosphate ester compound has been improved, the reduced persistence and generation of sediment thereof over time have been simultaneously inhibited, and the composition feels good instead of feeling odd when used; and a method for stabilizing ascorbic acid phosphate esters or salts thereof in liquid oral compositions. A liquid oral composition containing (A) an ascorbic acid phosphate ester or salt thereof and not containing an abrasive, wherein (B) an organic acid or salt thereof and (C) an ortho-phosphate have been mixed, pH has been set to be 6.5-8.0, and the water content has been set to be 60 mass% or more. A method for stabilizing ascorbic acid phosphate esters or salts thereof in liquid oral compositions, wherein component (B) and component (C) are mixed into a liquid oral composition containing component (A) and not containing an abrasive, the pH is set to be 6.5-8.0, and the water content is set to be 60 mass% or more.

Description

[Name of invention determined by ISA based on Rule 37.2] Liquid oral composition

The present invention relates to a liquid oral composition containing an ascorbic acid phosphate or a salt thereof and not containing an abrasive. More specifically, the ascorbic acid phosphate or a salt thereof is excellent in stability over time. Furthermore, the present invention relates to a liquid oral composition that can suppress the occurrence of orientation of the preparation and has a good feeling of use and good usability, and a method for stabilizing an ascorbic acid phosphate ester or a salt thereof in the liquid oral composition.

Ascorbic acid plays an important role in the expression of various enzyme activities in the living body and is known to have various physiological activities. In particular, it acts as a coenzyme for prolyl and lysyl hydroxylase, and is essential for collagen synthesis. For this reason, it is useful for the prevention and treatment of gingivitis and periodontitis accompanied by collagen destruction, and various ascorbic acid derivatives have been developed in the past. In particular, ascorbic acid phosphates and their salts have attracted attention.

However, when ascorbic acid phosphates were blended in the oral composition, there was a problem that the residual rate of ascorbic acid phosphates decreased with time. Especially in liquid oral compositions such as mouthwashes and liquid dentifrices, since the amount of water in the composition is large, the decrease in the residual rate is significant, and it is possible to suppress the decrease in the residual rate even after storage at high temperatures for a long time. It was very difficult.

Moreover, ascorbic acid phosphates are stable on the alkali side, and maintaining the pH of the composition in the alkaline region is effective in suppressing the decrease in the residual rate, but on the other hand, the pH of the liquid oral composition is When it exceeded 8, there was a problem that problems occurred in formulation, such as when it was put in the mouth, a feeling of discomfort such as a null taste or an unpleasant taste was felt, and it was easy to generate orientation.

To date, as a technique for stably blending ascorbic acid phosphates, Patent Document 1 (Japanese Patent Laid-Open No. 2000-256153) discloses a chelating agent having a carboxyl group and a phosphate group such as condensed phosphoric acid and phytic acid. The composition for oral cavity which prevented the residual rate fall with time of ascorbic acid or its derivative by mix | blending with the chelating agent which has is proposed. However, chelating agents having a phosphate group such as condensed phosphoric acid and phytic acid are different from orthophosphates, and may cause oliability over time, impairing the uniform appearance of the liquid oral composition. It was an issue. In Patent Document 2 (Japanese Patent Laid-Open No. 4-173727), coloring is performed by blending an abrasive with ascorbic acid phosphates and blending citric acid, phosphate, carbonate, bicarbonate, and the like. Although suppressed oral compositions have been proposed, the intensity of coloring does not necessarily match the degree of decrease in the residual rate of ascorbic acid phosphates. A water-insoluble compound such as an abrasive is difficult to be blended into a liquid oral composition, and this technique has been insufficient in inhibiting decomposition over time.
Patent Document 3 (Japanese Patent Laid-Open Publication No. Sho 62-63597) discloses a method for suppressing the occurrence of orientation in a composition containing ascorbic acid phosphates, in which organic carboxylic acid (salt), organic phosphoric acid (salt), organic According to Patent Document 4 (Japanese Patent Laid-Open No. 2002-255981), a method of blending a sulfate is L-ascorbic acid-2-phosphate magnesium having a reduced calcium compound content that is presumed to be a cause of the occurrence of sediment. Salts and methods for their production have been proposed. However, with these techniques, the effect of suppressing the decomposition of ascorbic acid phosphates is low, and it has been difficult to simultaneously solve the occurrence of sediment and the suppression of decomposition.

JP 2000-256153 A JP-A-4-173727 JP-A-62-63597 JP 2002-255981 A

In view of this, it is desirable to provide a new technique capable of stably providing ascorbic acid phosphates in a liquid oral composition, simultaneously solving the decrease in the residual rate and the occurrence of sediment, and providing a formulation with a good feeling of use. It is.
The present invention has been made in view of the above circumstances, and in a liquid oral composition containing ascorbic acid phosphates, the stability of the ascorbic acid phosphates is improved, and the ascorbic acid phosphates over time. The present invention provides a liquid oral composition having a good residual feeling and a reduced feeling of residual rate and occurrence of sediment in the liquid, and a method for stabilizing an ascorbic acid phosphate or a salt thereof in the liquid oral composition. For the purpose.

As a result of intensive studies to achieve the above object, the present inventors have (A) a liquid oral composition containing an ascorbic acid phosphate ester or a salt thereof and not containing an abrasive. Ascorbic acid is prepared by blending an acid or a salt thereof and (C) orthophosphate, adjusting the pH at 25 ° C. to 6.5 to 8.0, and the water content in the composition to 60% by mass or more. It has been found that the stability of phosphoric acid ester or a salt thereof and the effect of suppressing the orientation are well maintained.
According to the present invention, in a liquid oral composition containing an ascorbic acid phosphate or a salt thereof and not containing an abrasive, ascorbic acid can be stored at 60 ° C. for 1 month in the vicinity of a pH of 8 or less. Phosphoric acid ester or its salt can be stabilized, and ascorbic acid phosphoric acid ester or its salt is excellent in stability over time, the occurrence of orientation is effectively suppressed, and there is also a sense of incongruity when it is contained in the mouth. It has been found that a liquid oral composition having a good feeling of use can be provided, and the present invention has been made.

That is, according to the conventional technique, it is difficult to satisfactorily stabilize ascorbic acid phosphates in a liquid oral composition that does not contain an abrasive at a pH of 8 or lower, and an organic carboxylate such as citrate is not stable. The inhibitory effect was not sufficient. Ascorbic acid phosphates are combined with citrate, disodium phosphate and other phosphates to reduce coloration, and ascorbic acid phosphates are combined with citrate and pyrophosphate or tripolyphosphate. It is known that the residual rate can be prevented from decreasing by doing so. However, (B) an organic acid or a salt thereof and (C) an orthophosphate are used in combination, the pH of the composition is 6.5 to 8.0, and the water content in the composition is 60% by mass or more. As a result, even a liquid oral composition having a pH of 8 or less can effectively stabilize the ascorbic acid phosphate or a salt thereof, thereby reducing the residual rate of the ascorbic acid phosphate or the salt and generating an orientation. It is the present inventors' new knowledge that it can suppress simultaneously and can provide a favorable usability | use_condition.
In the present invention, the mechanism of action is not clear, but (B) an organic acid or a salt thereof and (C) an orthophosphate are used in combination with (A) ascorbic acid phosphate or a salt thereof. Thus, it is presumed that these components can act synergistically to simultaneously suppress the decrease in the residual rate of the ascorbic acid phosphate ester or a salt thereof and the occurrence of sediment.

Therefore, this invention provides the stabilization method of the ascorbic acid phosphate ester or its salt in the following liquid oral composition and liquid oral composition.
[1]
(A) An ascorbic acid phosphate ester or a salt thereof, and a liquid oral composition containing no abrasive, (B) an organic acid or a salt thereof and (C) an orthophosphate, A liquid oral composition, wherein the pH at the time is 6.5 to 8.0 and the water content in the composition is 60% by mass or more.
[2]
The liquid oral composition according to [1], wherein the blending ratio of the component (B) to the component (C) is 0.1 to 5 as a mass ratio of (B) / (C).
[3]
The liquid oral composition according to [1] or [2], containing 0.01 to 1% by mass of component (B) and 0.01 to 1% by mass of component (C).
[4]
(B) The composition for liquid oral cavity according to [1], [2] or [3], wherein the component is at least one selected from citric acid, malic acid, tartaric acid, succinic acid and salts thereof.
[5]
(A) An ascorbic acid phosphate ester or a salt thereof, and a liquid oral composition containing no abrasive, (B) an organic acid or a salt thereof and (C) an orthophosphate, Stabilization of an ascorbic acid phosphate ester or a salt thereof in the liquid oral composition, wherein the pH at the time is 6.5 to 8.0, and the water content in the composition is 60% by mass or more Method.
[6]
[5] The stabilization method according to [5], wherein the blending ratio of the component (B) to the component (C) is 0.1 to 5 as a mass ratio of (B) / (C).

According to the present invention, in a liquid oral composition containing an ascorbic acid phosphate or a salt thereof and not containing an abrasive, the ascorbic acid phosphate or a salt thereof can be stabilized even at a pH of 8 or lower. In addition, it is possible to provide a liquid oral composition having a good feeling of use without causing a sense of incongruity and suppressing a decrease in the residual rate of the ascorbic acid phosphate ester or a salt thereof over time and the occurrence of orientation.

Hereinafter, the present invention will be described in more detail.
The liquid oral composition of the present invention is a liquid oral composition that does not contain an abrasive, and (A) ascorbic acid phosphate ester or salt thereof, (B) organic acid or salt thereof, and (C) ortholine. An acid salt is contained, the water content in the composition is 60% by mass or more, and the pH at 25 ° C. is 6.5 to 8.0.

(A) Ascorbic acid phosphate or a salt thereof, ascorbic acid, one or more of the hydroxyl groups at positions 2, 3, 5, and 6 is an ester of a compound such as phosphoric acid or polyphosphoric acid. Examples thereof include ascorbic acid-2-phosphate, ascorbic acid-3-phosphate, ascorbic acid-6-phosphate, ascorbic acid-2-polyphosphate, and salts thereof. Examples thereof include alkali metal salts and alkaline earth metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt. In particular, from the viewpoint of stability of the composition, a derivative in which the hydroxyl group at the 2-position or 3-position of ascorbic acid is converted to a phosphate ester is preferable, and a magnesium salt or sodium salt of ascorbyl 2-phosphate ester is more preferable. .

(A) The blending amount of ascorbic acid phosphate or a salt thereof is preferably 0.1 to 5% (mass%, the same shall apply hereinafter), particularly 0.2 to 2% of the entire composition. If the blending amount is less than 0.1%, the preventive effect on periodontal disease may not be fully exerted. If the amount exceeds 5%, further improvement in the preventive effect on periodontal disease cannot be expected, and a strange taste occurs. There are cases where the user feels uncomfortable when the product is contained in the mouth and is inferior in use.

The (B) component organic acid or salt thereof is blended as a stabilizer for the (A) component. When used in combination with the (C) component, the effect of inhibiting decomposition of the (A) component and the occurrence of orientation of the preparation are generated. And the effect which suppresses discomfort expression is exhibited.
Component (B) is not particularly limited as long as it is an organic acid that is usually blended in oral compositions, but di- or tricarboxylic such as tartaric acid, malic acid, succinic acid, glutamic acid, adipic acid, aspartic acid, citric acid and the like. Acid is preferred. Moreover, as those salts, a sodium salt, potassium salt, etc. are preferable. Among these, tartaric acid, malic acid, succinic acid, citric acid or a salt thereof are particularly preferable, more preferable from the viewpoint of the decomposition suppressing effect of the component (A), the effect of suppressing the orientation, and the discomfort when contained in the mouth. Is citric acid or its sodium salt.

The organic acid or salt thereof may be blended alone or in combination of two or more, but the blending amount is 0.01 to 1%, particularly 0.03 to 0.5% of the total composition. preferable. If the blending amount is less than 0.01%, the effect of suppressing the decomposition of the component (A) and the effect of suppressing the orientation may be inferior. If the amount exceeds 1%, the effect of suppressing the decomposition of the component (A) is reduced, and further taste is generated. There may be a greater sense of discomfort when put in the mouth.

The orthophosphate salt of the component (C) is blended as a stabilizer for the component (A). When used in combination with the component (B), the effect of inhibiting the decomposition of the component (A) and the occurrence of orientation of the preparation Demonstrates the effect of suppressing the appearance of discomfort.
Orthophosphates include orthophosphates such as sodium phosphate, potassium phosphate and ammonium phosphate, monosodium dihydrogen phosphate, disodium monohydrogen phosphate, monopotassium dihydrogen phosphate, dipotassium hydrogen phosphate, etc. A hydrogen salt is mentioned. Especially, from the point of the decomposition | disassembly inhibitory effect of (A) component, and the restraint effect, a hydrogen salt is preferable, More preferably, it is disodium monohydrogen phosphate. Note that the object of the present invention cannot be achieved by using a chelating agent having a phosphate group such as pyrophosphate or polyphosphate instead of orthophosphate.

The blending amount of orthophosphate is preferably 0.01 to 1%, particularly 0.03 to 0.5% of the whole composition. If the blending amount is less than 0.01%, the decomposition inhibitory effect of the component (A) may be inferior. If it exceeds 1%, the decomposition inhibitory effect and the orientation inhibitory effect of the component (A) are reduced, and further off-flavors are generated. There may be a greater sense of discomfort when put in the mouth.

The blending ratio of component (B) to component (C) is such that (B) component / (C) component is 0.1 to 5, particularly 0.2 to 3 in terms of mass ratio. It is preferable from the viewpoint of the decomposition suppressing effect and the orientation suppressing effect. When the blending ratio is less than 0.1, or when it exceeds 5, the (A) component decomposition inhibiting effect and the orientation inhibiting effect may not be sufficiently exhibited. In particular, the above blending ratio is more effective for satisfactorily exhibiting the restraining effect.

Further, the ratio of ((B) component + (C) component) / (A) component is preferably 0.05 to 5, particularly 0.1 to 1 in terms of mass ratio, and such a ratio. However, it is more preferable from the viewpoint of improving the decomposition suppressing effect of the component (A). When the ratio is less than 0.05 or exceeds 5, the effect of inhibiting the decomposition of component (A) may not be sufficiently exhibited.

In the composition of the present invention, purified water is generally blended as a solvent. The amount of water is 60% or more of the whole composition, preferably 75% or more, and desirably less than 99.8%. If the amount of water is less than 60%, you may feel nulliness or stickiness in the oral cavity, and the irritation in the oral cavity by other solvents such as alcohol may increase, resulting in a greater sense of discomfort when contained in the mouth. There is sex.

The pH of the composition is 6.5 to 8.0 (25 ° C.), more preferably 7.0 to 7.8. If the pH is less than 6.5, the effect of inhibiting the decomposition of the component (A) is reduced, and if it exceeds 8.0, the orientation cannot be satisfactorily suppressed, and when it is contained in the mouth, a sense of incongruity such as a stickiness or a nasty taste increases. there is a possibility.

The pH of the composition may be 6.5 to 8.0 in some cases, but may be adjusted within the above range using a pH adjuster as necessary. As the pH adjusting agent, a pH adjusting agent such as sodium hydroxide, hydrochloric acid, sodium carbonate, sodium hydrogen carbonate, boric acid or a salt thereof can be used, and among them, sodium hydroxide, potassium hydroxide and hydrochloric acid are preferably used. The blending amount of these pH adjusters only needs to be able to adjust the pH to the above range.

The liquid oral composition of the present invention can further contain a solvent, a wetting agent, or the like, if necessary. As the solvent, a polyhydric alcohol such as propylene glycol and a lower alcohol such as ethanol can be blended. The amount of these solvents is usually from 0 to 30% of the whole composition, and preferably from 2 to 20%.
The liquid oral composition of the present invention is a composition that substantially does not contain ethanol (that is, the ethanol content in the composition is 0.01% or less, particularly 0 to 0.0001%). Also, the effects of the present invention can be obtained.

Examples of the wetting agent include polyhydric alcohols and sugar alcohols such as sorbitol, glycerin, ethylene glycol, polyethylene glycol, xylitol, and erythritol. The amount is usually 0 to 20% of the entire composition.

The liquid oral composition of the present invention is a liquid oral composition that does not contain an abrasive, and is a dosage form such as a mouthwash, a liquid toothpaste, a dentifrice gel, a mouth freshener, a concentrated mouthwash, and particularly a mouthwash. It can be suitably prepared and applied as an agent. The mouthwash may be transparent or opaque, but is preferably a uniform liquid containing no precipitate or suspended matter. Moreover, according to the dosage form, an appropriate well-known component can be mix | blended as needed other than the said component. For example, in addition to the above solvent and wetting agent, thickeners, surfactants, preservatives, sweeteners, colorants, fragrances, active ingredients and the like can be blended.

Examples of the thickener include sodium carboxymethyl cellulose, hydroxyethyl cellulose and the like. The blending amount of the thickener is usually 0 to 5%, particularly 0.1 to 3%.

As the surfactant, a surfactant that is widely used in oral compositions can be used, and the amount of the surfactant is usually in the range of 0.1 to 10%.

Examples of preservatives include parabens. Examples of the sweetening agent include saccharin sodium. Examples of the colorant include water-soluble pigments.

As perfumes, natural perfumes such as spearmint oil and peppermint oil, and single perfumes such as carvone and anethole, as well as well-known perfumes used in oral hygiene products such as single perfumes and / or blended perfumes including natural perfumes are used. It is not limited to the fragrances described in the examples. Usually, the blending amount is in the range of 0.00001 to 1%.

As an active ingredient, in addition to the ascorbic acid phosphate ester (A) or a salt thereof, an effective amount of, for example, an anti-inflammatory agent, an enzyme, a fluoride, a bactericidal agent, etc., is included within a range not impeding the effects of the present invention. May be.

Hereinafter, although an Example and a comparative example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example. In the following examples,% indicates mass% unless otherwise specified. The pH in the table was measured using a pH meter (model number Hm-30S) manufactured by Toa Denpa Kogyo immediately after the composition was prepared, and showed a value after 3 minutes at 25 ° C.

Examples and comparative examples
Liquid oral compositions having the compositions shown in Tables 1 to 3 were prepared by the following method to obtain uniform liquid oral compositions. The liquid oral composition obtained was transparent. These liquid oral compositions were evaluated by the following methods. The results are also shown in Tables 1 to 3.

(1) Preparation Method of Liquid Oral Composition Ascorbic acid phosphates and other components were mixed with 850 g of purified water at room temperature and stirred for 1 hour until the ascorbic acid phosphates were completely dissolved. If the pH does not fall within the range of 6.5 to 8.0, adjust the pH with sodium hydroxide, hydrochloric acid, etc., and then use purified water so that the total amount of the composition becomes 1,000 g. It was adjusted. In addition, sodium hydroxide and hydrochloric acid prepared 10% aqueous solution, and added so that pH might be in the said range.

(2) Evaluation of decomposition inhibitory effect of component (A) 250 mL of the composition was filled in a 250 mL PET container, stored at 60 ° C. and −5 ° C. for 1 month, and then 10 mmol / L phosphate buffer ( Diluted and filtered with 1.5 mmol / L potassium dihydrogen phosphate, 23.5 mmol / L dipotassium hydrogen phosphate, pH 8), high-performance liquid chromatography (pump: PU1580 manufactured by JASCO Corporation, autosampler: Shimadzu Corporation) SIL-10A manufactured by Seisakusho, UV detector: SPD-6A manufactured by Shimadzu Corporation, and recording device: C-R4A manufactured by Shimadzu Corporation were used for quantification by the absolute calibration curve method. The mobile phase is a 25 mmol / L potassium dihydrogen phosphate + 5 mmol / L tetrabutylammonium sulfate / acetonitrile = 91/9 mixture (volume ratio), the column is a stainless steel tube having a diameter of about 4.6 mm and a length of about 150 mm, and a 5 μm liquid chromatograph. One filled with octadecylsilylated silica gel for graphs (example: TSK-gel ODS-80Ts (manufactured by Tosoh Corporation)), column temperature of about 50 ° C., detection wavelength of 240 nm, and flow rate of 0.8 mL / min. The concentration of ascorbic acid phosphates in the product stored at 60 ° C. was calculated, and the residual ratio when the content in the product stored at −5 ° C. was taken as 100% was determined.
Evaluation criteria for decomposition inhibition of ascorbic acid phosphates ◎: Residual rate in composition is 90% or more ○: Residual rate in composition is 80% or more and less than 90% △: Residual rate in composition is 70% or more Less than 80% x: Residual ratio in composition is less than 70%

(3) Evaluation of orientation suppression effect A PET container filled with 250 ml of the composition in a 250 mL PET container and stored at 60 ° C. for 1 month, and then the PET container gently filled with purified water. In comparison with (control product), visual judgment was made according to the following criteria.
Evaluation criteria for orientation suppression effect ◎: No sedimentation sedimentation ○: Slight sedimentation orientation is observed slightly, but no problem △: sedimentation sedimentation is clearly recognized ×: Orientation is recognized without transposition of PET container

(4) Evaluation of no discomfort when put in mouth By 10 subjects with sensitive oral mucosa, the composition is contained in about 10 mL mouth, and the discomfort felt in the mouth while rinsing for about 20 seconds is a control. The product was subjected to sensory evaluation according to the following criteria in comparison with the product (the same composition as in Example 1 and adjusted to pH 9 with sodium hydroxide as a pH adjusting agent), and the average value was determined and judged according to the following criteria.
Evaluation Criteria for No Discomfort When Ingested 4: Remarkably Discomfort was Low 3: Discomfort was Low and No Problem Level 2: Equivalent Discomfort 1: Remarkable Discomfort Criteria ◎: 3.5 points or more ○: 3.0 points or more and less than 3.5 points △: 2.0 points or more and less than 3.0 points ×: Less than 2.0 points

Details of the raw materials used are as follows.
Phosphoric acid-L-ascorbyl magnesium: manufactured by Wako Pure Chemical Industries, Ltd. Biochemical phosphoric acid-L-ascorbyl sodium: manufactured by DSM Nutrition Japan, Inc. Product name Stay C50
Citric acid monohydrate: manufactured by Fuso Chemical Industry Co., Ltd., citric acid, outer general grade (standard product for quasi-drugs)
Trisodium citrate dihydrate: manufactured by Fuso Chemical Industry Co., Ltd., sodium citrate, outer general grade disodium malate 0.5 hydrate: manufactured by Kanto Chemical Co., Ltd., special grade disodium succinate: manufactured by Kanto Chemical Co., Ltd. Special grade L-tartaric acid: manufactured by Kanto Chemical Co., Ltd. Special grade monohydrogen phosphate disodium: manufactured by Taihei Chemical Sangyo Co., Ltd., sodium monohydrogen phosphate, external original grade boric acid: manufactured by Kanto Chemical Co., special grade (comparative product)
Carbonic acid: manufactured by Kanto Chemical Co., Ltd., special grade (comparative product)
Sodium pyrophosphate: Taihei Chemical Industry Co., Ltd.
Polyphosphoric acid: manufactured by Taihei Chemical Industry Co., Ltd., sodium polyphosphate, outer original standard grade (comparative product)
Glycerin: Propylene glycol manufactured by Lion Chemical Co., Ltd .: Asahi Glass Co., Ltd. Sodium hydroxide: manufactured by Kanto Chemical Co., Inc. Sodium hydroxide, special grade diluted to 10% Hydrochloric acid: manufactured by Kanto Chemical Co., hydrochloric acid, special grade diluted to 10% Mix

Claims

(A) An ascorbic acid phosphate ester or a salt thereof, and a liquid oral composition containing no abrasive, (B) an organic acid or a salt thereof and (C) an orthophosphate, A liquid oral composition, wherein the pH at the time is 6.5 to 8.0 and the water content in the composition is 60% by mass or more.
The liquid oral composition according to claim 1, wherein the blending ratio of the component (B) to the component (C) is 0.1 to 5 as a mass ratio of (B) / (C).
3. The composition for liquid oral cavity according to claim 1 or 2, comprising 0.01 to 1% by mass of component (B) and 0.01 to 1% by mass of component (C).
The liquid oral composition according to claim 1, 2 or 3, wherein the component (B) is at least one selected from citric acid, malic acid, tartaric acid, succinic acid and salts thereof.
(A) An ascorbic acid phosphate ester or a salt thereof, and a liquid oral composition containing no abrasive, (B) an organic acid or a salt thereof and (C) an orthophosphate, Stabilization of an ascorbic acid phosphate ester or a salt thereof in the liquid oral composition, wherein the pH at the time is 6.5 to 8.0, and the water content in the composition is 60% by mass or more Method.
The stabilization method according to claim 5, wherein the blending ratio of the component (B) and the component (C) is 0.1 to 5 as a mass ratio of (B) / (C).